Turning cancer defects into cures

With a team of 70 scientists from 22 different nations we turn cancer defects into novel treatments. Subscribe to our newsletter to stay updated about our research!

“Our commitment doesn’t stop with with science at the basics;  we bring it all the way to the patients.

We improve Science, Health and Society”

 

 

 

The Helleday Laboratory consists of a large team of mixed professions; basic molecular biologists, medicinal chemists from industry and academia, pharmacologists, biochemists and practising clinicians, amongst others.

What brings us together is our dedication to make our basic science discoveries reach all the way to helping patients stay healthy and with their loved ones!

The Helleday Laboratory focuses on metabolism and DNA repair.

Nobel Prize laureate Otto Warburg pioneered cancer metabolism and coined that “The cure of human cancer will be the resultant of biochemistry of cancer and of biochemistry of man“. We think he was right, and with the molecular knowledge of altered metabolic pathways in cancer of today we can make real advances in progressing treatments. Read about how we target glucose metabolism and nucleotide metabolism.

Chemo- and radiotherapy is still the backbone of cancer treatments today and work by causing DNA damage. We know today that cancer cells have a high load of DNA damage as compared to normal cells. Read about DNA damage and repair in cancer. Previously, the Helleday lab has exploited this and shown that PARP inhibitors selectively kill recombination defective cancers, such as inherited breast- and ovarian cancer. This is now an approved treatment and help patients across the world.


Our metabolic target MTHFD2 crystal structure now resolved with inhibitor

The MTHFD2 protein is uniquely expressed in cancer and not in normal tissue. Yet, it is required for survival in cancer, but not for normal cells. This makes it a highly interesting target, with the potential of finding compounds that selectively kill cancer cells,...

The Helleday Team presents potent MTH1 inhibitor ‘Karonudib’ and experimentally addresses the non-active MTH1 inhibitors.

The Helleday Team proudly presents our new potent MTH1 inhibitor Karonudib, which is 20 times more effective than the previously described TH588 inhibitor, recently published in Annals of Oncology. Karonudib stands for: Karolinska nudt1 (MTH1 gene name) inhibitor. In...

Dr Firas Tarish celebrates his new doctor hat in the City Hall

...

New EU funding a large training network across Europé on novel approaches to treat cancer

Thomas Helledays receives ERC Advanced Grant

Thomas Helledays receives ERC Advanced Grant Thomas Helleday is one of nine scientists receiving a grant of 2.5 million euros over five years from the European Research Council. Research proposed for funding to the ERC should aim high, both with regards to the...


News

Congratulations Saeed Eshtad, PhD!

The Helleday lab wishes to congratulate Saeed Eshtad on a successful thesis defence on Monday February 13th! Saeeds’s thesis is called “Targeting DNA repair pathways for cancer therapy” and the aim of the thesis was to identify and understand if factors important in...

“I am naturally happy and impressed by your work. Words can not describe how grateful I am; not only for my sake but for my children and family as well. It gives me hope to break the chain of cancer in the family. I hope for the drug to reach the market soon so more can be treated.” Translated from Swedish

Marie

Stockholm

Our vision

Many diseases have alterations in metabolic pathways often leading to DNA damage that manifest or define the disease. Our strategy is to identify basic mechanisms of proteins involved in metabolism and DNA repair to gain better understanding in disease and also develop small molecule inhibitors to selectively targeting these proteins as potential therapeutics. We reach our goal through open innovation and through a foundation, securing the future for our science and ensuring long term benefit to mankind.

Our mission

We turn cancer defects into novel treatments. Cancer cells already have altered metabolic activity and a lot of DNA damage. With specific metabolic or DNA repair inhibitors we force the cancer cell into a trap where they cannot cope with the overload of DNA damage, without harming healthy cells with normal metabolic pathways.

There are 2 major kinds of motorcycle chanel replica saddlebags. Throw over saddlebags and hard mount saddlebags. The concept of hard mount saddlebags originated from throw over saddlebags which were used in early 1950 for your first time. As the motorcycle business experienced a big boom in 1960 especially after the chanel replica sale the motorcycle luggage also evolved. As major motorcycle companies launched bigger and better motorcycle folks chanel replica sale began traveling farther on there motorcycles. Many riders formed groups and chanel replica rode cross country and from city to city. Chanel replica handbags outlet is your trusting choosing. This permanent installation resulted in the saddlebags is more reliable and sturdy.